Results 1 to 10 of about 114,558 (301)

Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor [PDF]

Drug Design, Development and Therapy, 2022
Xu Yang,1 Amin Liu,1 Lin Yang,1 Tiantian Wen,2 Jia Wang,3 Jingmiao Shi,3 Hui Zhou,2 Zhimeng Chen,1 Meng Lei,1 Yongqiang Zhu2 1College of Science, Nanjing Forestry University, Nanjing, People’s Republic of China; 2College of Life Science, Nanjing Normal ...
Yang X, Liu A, Yang L, Wen T, Wang J, Shi J, Zhou H, Chen Z, Lei M, Zhu Y   +9 more
doaj   +2 more sources

Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin [PDF]

ADMET and DMPK
Background and purpose: Disitamab vedotin is an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody (mAb) targeting HER2 conjugated to monomethyl auristatin E(MMAE) via a cleavable dipeptide linker.
Ling Wang, Limeng Zhu, Fengzhu Wang, Lihou Dong, Zhihao Liu, Fang Chen, Jing Jiang   +6 more
doaj   +2 more sources

Effects of bariatric surgery on drug pharmacokinetics—Preclinical studies

Frontiers in Pharmacology, 2023
With the rising worldwide obesity rates, bariatric surgeries are increasing. Although the surgery offers an effective treatment option for weight loss, the procedure causes dramatic physiological and metabolic changes.
Angela Mercado, Anna Pham, Zhijun Wang, Wendong Huang, Patrick Chan, Hajer Ibrahim, Hyma Gogineni, Ying Huang, Jeffrey Wang   +8 more
exaly   +3 more sources

Using Miniature MS System with Automatic Blood Sampler for Preclinical Pharmacokinetics Study [PDF]

Bioanalysis, 2017
Fan Pu, Wenpeng Zhang, Kevin P Bateman
exaly   +2 more sources

Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics

Frontiers in Pharmacology, 2021
Protein therapeutics have witnessed tremendous use and application in recent years in treatment of various diseases. Predicting efficacy and safety during drug discovery and translational development is a key factor for successful clinical development of
Vittal Shivva, C. Andrew Boswell, Hanine Rafidi, Robert F. Kelley, Amrita V. Kamath, Susan R. Crowell   +5 more
doaj   +1 more source

Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies

mAbs, 2022
Advances in antibody engineering have enabled the construction of novel molecular formats in diverse shapes and sizes, providing new opportunities for biologic therapies and expanding the need to understand how various structural aspects affect their ...
Hanine Rafidi, Sharmila Rajan, Konnie Urban, Whitney Shatz-Binder, Keliana Hui, Gregory Z. Ferl, Amrita V. Kamath, C. Andrew Boswell   +7 more
doaj   +1 more source

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)

Pharmaceutics, 2023
The field of targeted protein degradation is growing exponentially. Yet, there is an unmet need for pharmacokinetic/pharmacodynamic models that provide mechanistic insights, while also being practically useful in a drug discovery setting.
Robin Thomas Ulrich Haid, Andreas Reichel   +1 more
doaj   +1 more source

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

Frontiers in Pharmacology, 2022
ACT-1004-1239 is a potent, selective, first-in-class CXCR7 antagonist, which shows a favorable preclinical and clinical profile. Here we report the metabolites and the metabolic pathways of ACT-1004-1239 identified using results from in vitro and in vivo
Christine Huynh, Christine Huynh, Swen Seeland, Jerome Segrestaa, Carmela Gnerre, Jens Hogeback, Henriette E. Meyer zu Schwabedissen, Jasper Dingemanse, Patricia N. Sidharta   +8 more
doaj   +1 more source

Expression and Function of ABC Transporters in Human Alveolar Epithelial Cells

Biomolecules, 2022
ATP-binding cassette (ABC) transporters are a large superfamily of membrane transporters that facilitate the translocation of different substrates. While ABC transporters are clearly expressed in various tumor cells where they can play a role in drug ...
Rossana Visigalli, Bianca Maria Rotoli, Francesca Ferrari, Maria Di Lascia, Benedetta Riccardi, Paola Puccini, Valeria Dall’Asta, Amelia Barilli   +7 more
doaj   +1 more source

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

Pharmaceutics, 2022
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively.
Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath, Meric A. Ovacik   +18 more
doaj   +1 more source